The COVID-19 vaccine industry has seen immense investor backing with popular US listed companies such as Moderna, Pfizer and Vaxart multiplying their pre-COVID value upwards of 500%-1,000%. However, Novavax, Inc. (NASDAQ: NVAX) has surpassed it’s rivals in stock value growth, currently priced at $143.10. An investment of $10,000 in NVAX after the initial COVID-19 vaccine announcement in March, would now be worth over $207,000. Investors found promise in Novavax as the US Government committed to $1.6 Billion in late clinical trial funding.

Table of Contents 
1. How much a $10,000 investment in NVAX is now worth?
2. Breakdown on rivals and vaccine development 
3. What experts expect NVAX price to hit by 2021?

Breakdown on rivals and vaccine development

The current COVID-19 vaccine industry has been operating at a rapid pace. The Warp Speed operation set up by the US Government has narrowed down the list of contenders to a handful. Moderna, Astra Zeneca and Pfizer are currently leading the pack as they push to the final stages of their COVID-19 vaccine trials.

What separates Novavax from its competitors, is its continued Government funding for vaccine development and manufacturing. Recent funding includes the $1.6 Billion from the US Government and $388 million from the Coalition for Epidemic Preparedness. This is alongside it’s other multi-million dollar venture, Nano Flu. This Flu vaccine has acted as a safety net for investors,  in the event the COVID-19 vaccine NVX-CoV2373 fails to reach the distribution phase.

What experts expect NVAX to hit by 2021?

Before I begin, I am obliged to remind our viewers that this is not financial advice but rather investment commentary from extensive research.

The expectations for vaccine developers such as NVAX are extraordinarily high. The challenge of developing a safe and effective vaccine during a pandemic is somewhat an overwhelming task. The progress of Novavax’s vaccine NVX-CoV2373 so far has been outstanding. This has marked NVAX as one of the key players in the COVID-19 race. The current price targets for Novavax on the Wallstreet Journal are averaged at $132, with a bullish target at $182 and a bearish prediction of $105. These current price targets suggest a flat short term future for NVAX.

However, price targets will continuously change in this industry as speculators move between each company on news. The positives for investors are NVAX has been able to restructure their business model into a profitable prospect by 2021-22. If NVAX can secure a safe and effective vaccine, alongside their project Nano-Flu, we could be looking at one of the biggest success stories in Bio-Pharma history to date (opinion).

The information above is not financial advice. Youth Investment Group has no liability for personal financial interests or investment decisions. You should make your own investment decisions based upon your own research and what you believe is best for you.

Leave a comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.